Search Results (214)

Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Radiomics and artificial intelligence (AI) have emerged as promising tools for quantitative imaging analysis and precision staging. This study aimed to evaluate the ability of an AI-based radiomics model to preoperatively predict tumor (T) and nodal (N) stage, lymphovascular invasion (LVI), and postoperative complications in patients with early-stage NSCLC. Material and Methods: This retrospective study included 51 consecutive patients who underwent anatomical lobectomy with systematic lymph node dissection between 2019 and 2024, at the Clinic for Thoracic Surgery of the University Clinical Center of Serbia. Quantitative imaging features were extracted from preoperative CT scans using the Lesion Scout with Auto ID module (syngo.via VB50 MM, Siemens Healthineers). Radiomics and clinical predictors were analyzed using regularized logistic regression (LASSO) with five-fold cross-validation. Model performance was assessed using AUC, accuracy, sensitivity, specificity, precision, and F1 score, and calibration was evaluated using the Hosmer–Lemeshow test. Groups were compared using parametric and non-parametric tests. Correlation between the variables was assessed using Spearman’s rank correlation coefficient. All p-values less than 0.05 were considered significant. Results: The AI-based model showed excellent performance for predicting the T component (training AUC = 0.89; test AUC = 0.86; F1 = 0.81) and acceptable calibration (p = 0.41). Nodal metastasis (OR = 0.108; 95% CI: 0.011–1.069; p = 0.057) and LVI (OR = 0.519; 95% CI: 0.139–1.937; p = 0.329) were not significantly predicted. Emphysema was identified as a significant independent predictor of postoperative complications (χ² = 5.13; p = 0.024). Conclusions: The AI-driven radiomics model demonstrated strong predictive ability for the T component and identified emphysema as a clinically relevant predictor of postoperative complications. Full article

Radiomics has emerged as a promising tool for non-invasive tumour phenotyping in breast cancer, providing valuable insights into tumour heterogeneity, response prediction, and risk stratification. However, traditional radiomic approaches often rely on correlative patterns of image analysis to clinical data and lack direct biological interpretability. Combining information provided by radiomics with genomics or other multi-omics data can be important to personalise diagnostic and therapeutic work up in breast cancer management. This review aims to explore the current progress in integrating radiomics with multi-omics data—genomics and transcriptomics—to establish biologically grounded, multidimensional models for precision management of breast cancer. We will review recent advances in integrative radiomics and radiogenomics, highlight the synergy between imaging and molecular profiling, and discuss emerging machine learning methodologies that facilitate the integration of high-dimensional data. Applications of radiogenomics, including breast cancer subtype and molecular mutation prediction, radiogenomic mapping of the tumour immune microenvironment, and response forecasting to immunotherapy and targeted therapies, as well as lymph nodes involvement, will be evaluated. Challenges in technical limitations including imaging modalities harmonization, interpretability, and advancing machine learning methodologies will be addressed. This review positions integrative radiogenomics as a driving force for next-generation breast cancer care. Full article

Background: Biopsy remains the gold standard for characterizing breast cancer, but it is invasive, costly, and may not fully capture tumor heterogeneity. Advances in artificial intelligence (AI) now allow for the extraction of biological and clinical information from medical images, raising the possibility of using imaging as a non-invasive alternative. Methods: A semi-systematic review was conducted to identify AI-based approaches applied to mammography (MM) and breast tomosynthesis (BT) for tumor subtyping, staging, and prognosis. A PubMed search retrieved 1091 articles, of which 81 studies met inclusion criteria (63 MM, 18 BT). Studies were analyzed by clinical target, modality, AI pipeline, number of cases, dataset type, and performance metrics (AUC, accuracy, or C-index). Results: Most studies focused on tumor subtyping, particularly receptor status and molecular classification. Contrast-enhanced spectral mammography (CESM) was frequently used in radiomics pipelines, while end-to-end deep learning (DL) approaches were increasingly applied to MM. Deep models achieved strong performance for ER/PR and HER2 status prediction, especially in large datasets. Fewer studies addressed staging or prognosis, but promising results were obtained for axillary lymph node (ALN) metastasis and pathological complete response (pCR). Multimodal and longitudinal approaches—especially those combining MM or BT with MRI or ultrasound—show improved accuracy but remain rare. Public datasets were used in only a minority of studies, limiting reproducibility. Conclusions: AI models can predict key tumor characteristics directly from MM and BT, showing promise as non-invasive tools to complement or even replace biopsy. However, challenges remain in terms of generalizability, external validation, and clinical integration. Future work should prioritize standardized annotations, larger multicentric datasets, and integration of histological or transcriptomic validation to ensure robustness and real-world applicability. Full article

Accurate preoperative staging of bladder cancer on MRI remains challenging because visual reads vary across observers. We investigated a multiparametric MRI (mpMRI) radiomics approach to predict muscle invasion (≥T2) and prospectively tested it on a validation cohort. Eighty-four patients with urothelial carcinoma underwent 1.5-T mpMRI per VI-RADS (T2-weighted imaging and DWI-derived ADC maps). Two blinded radiologists performed 3D tumor segmentation; 37 features per sequence were extracted (LifeX) using absolute resampling. In the training cohort (n = 40), features that differed between non-muscle-invasive and muscle-invasive tumors (Mann–Whitney p < 0.05) underwent ROC analysis with cut-offs defined by the Youden index. A compact descriptor combining GLRLM-LRLGE from T2 and GLRLM-SRLGE from ADC was then fixed and applied without re-selection to a prospective validation cohort (n = 44). Histopathology within 6 weeks—TURBT or cystectomy—served as the reference. Eleven T2-based and fifteen ADC-based features pointed to invasion; DWI texture features were not informative. The descriptor yielded AUCs of 0.934 (training) and 0.871 (validation) with 85.7% sensitivity and 96.2% specificity in validation. Collectively, these findings indicate that combined T2/ADC radiomics can provide high diagnostic accuracy and may serve as a useful decision support tool, after multicenter, multi-vendor validation. Full article

Breast cancer is one of the major health threats to women worldwide; thus, a need has arisen to reduce the number of instances and deaths through new methods of diagnostic monitoring and treatment. The present review is the synthesis of the recent clinical studies and technological advances in the application of magnetic resonance imaging (MRI) to monitor the pharmacological treatment of breast cancer. The specific focus is on high-risk groups (carriers of BRCA mutations and recipients of neoadjuvant chemotherapy) and the use of novel MRI methods (dynamic contrast-enhanced (DCE) MRI, diffusion-weighted imaging (DWI), and radiomics tools). All the reviewed studies show that MRI is more sensitive (up to 95%) and specific than conventional imaging in detecting malignancy particularly in dense breast tissue. Moreover, MRI can be used to assess the response and residual disease in a tumor early and accurately for personalized treatment, de-escalate unneeded interventions, and maximize positive outcomes. AI-based radiomics combined with deep-learning models also expand the ability to predict the therapeutic response and molecular subtypes, and can mitigate the risk of overfitting models when using complex methods of modeling. Other developments are hybrid PET/MRI, image guidance during surgery, margin assessment intraoperatively, three-dimensional surgical templates, and the utilization of MRI in surgery planning and reducing reoperation. Although economic factors will always play a role, the diagnostic and prognostic accuracy and capability to aid in targeted treatment makes MRI a key tool for modern breast cancer. The growing complement of MRI and novel curative approaches indicate that breast cancer patients may experience better survival and recuperation, fewer recurrences, and a better quality of life. Full article

Background: Lung cancer remains the leading cause of cancer-related mortality globally, largely due to delayed diagnosis in its early stages. While conventional diagnostic tools like low-dose CT and tissue biopsy are routinely used, they suffer from limitations including invasiveness, radiation exposure, cost, and limited sensitivity for early-stage detection. Liquid biopsy, a minimally invasive alternative that captures circulating tumor-derived biomarkers such as ctDNA, cfRNA, and exosomes from body fluids, offers promising diagnostic potential—yet its sensitivity in early disease remains suboptimal. Recent advances in Artificial Intelligence (AI) and radiomics are poised to bridge this gap. Objective: This review aims to explore how AI, in combination with radiomics, enhances the diagnostic capabilities of liquid biopsy for early detection of lung cancer and facilitates personalized monitoring strategies. Content Overview: We begin by outlining the molecular heterogeneity of lung cancer, emphasizing the need for earlier, more accurate detection strategies. The discussion then transitions into liquid biopsy and its key analytes, followed by an in-depth overview of AI techniques—including machine learning (e.g., SVMs, Random Forest) and deep learning models (e.g., CNNs, RNNs, GANs)—that enable robust pattern recognition across multi-omics datasets. The role of radiomics, which quantitatively extracts spatial and morphological features from imaging modalities such as CT and PET, is explored in conjunction with AI to provide an integrative, multimodal approach. This convergence supports the broader vision of precision medicine by integrating omics data, imaging, and electronic health records. Discussion: The synergy between AI, liquid biopsy, and radiomics signifies a shift from traditional diagnostics toward dynamic, patient-specific decision-making. Radiomics contributes spatial information, while AI improves pattern detection and predictive modeling. Despite these advancements, challenges remain—including data standardization, limited annotated datasets, the interpretability of deep learning models, and ethical considerations. A push toward rigorous validation and multimodal AI frameworks is necessary to facilitate clinical adoption. Conclusion: The integration of AI with liquid biopsy and radiomics holds transformative potential for early lung cancer detection. This non-invasive, scalable, and individualized diagnostic paradigm could significantly reduce lung cancer mortality through timely and targeted interventions. As technology and regulatory pathways mature, collaborative research is crucial to standardize methodologies and translate this innovation into routine clinical practice. Full article

Background/Objectives: Radiomics is a powerful and emerging tool in oncology, with many potential applications in predicting therapy response and prognosis. To assess the current state of radiomics in melanoma, we conducted a systematic review of its various clinical uses. Methods: We searched three databases: PubMed, Web of Science and Scopus. Each study was classified based on multiple variables, including patient number, metastasis number, therapy, imaging modality, clinical endpoints and analysis methods. The risk of bias in the systematic review was assessed with QUADAS-2, and the certainty of evidence in the meta-analysis with GRADE. Results: Forty studies involving 4673 patients and 24,561 lesions were included in the analysis. Metastatic disease was the most frequently studied clinical setting (85%). Immunotherapy was the most commonly investigated treatment, featured in half of the studies. Computed tomography (CT) was the preferred imaging modality, appearing in 17 studies (42.5%). Radiomic features were most often extracted using three-dimensional (3D) analysis (72.5%). Across 24 studies investigating the prediction of treatment response and survival, only 9 provided sufficient data (Area Under the Curve, AUC, and standard error, SE) for inclusion. A random-effects model estimated a pooled AUC of 0.83 (95% CI: 0.74 to 0.92), indicating strong discriminative performance of the radiomic models included. Low to moderate heterogeneity was observed (I² = 28.6%, p = 0.4741). No evidence of publication bias was detected (p = 0.470). Conclusions: Radiomics is increasingly being explored in the context of melanoma, particularly in advanced disease settings and in relation to immunotherapy. Most studies rely on CT imaging and 3D feature extraction, while molecular integration remains limited. Despite promising findings with strong discriminative performance in predicting therapy response, further prospective, standardized studies with higher methodological rigor are needed to validate radiomic biomarkers and integrate them into clinical decision-making. Full article

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Accurate determination of epidermal growth factor receptor (EGFR) mutation status is essential for selecting patients eligible for tyrosine kinase inhibitors (TKIs). However, invasive genotyping is often limited by tissue accessibility and sample quality. This study presents a non-invasive machine learning model combining clinical data, CT morphological features, and radiomic descriptors to predict EGFR mutation status. A retrospective cohort of 138 patients with confirmed EGFR status and pre-treatment CT scans was analyzed. Radiomic features were extracted with PyRadiomics, and feature selection applied mutual information, Spearman correlation, and wrapper-based methods. Five Random Forest models were trained with different feature sets. The best-performing model, based on 11 selected variables, achieved an AUC of 0.91 (95% CI: 0.81–1.00) under stratified five-fold cross-validation, with an accuracy of 0.88 ± 0.03. Subgroup analysis showed that EGFR-WT had a performance of precision 0.93 ± 0.04, recall 0.92 ± 0.03, F1-score 0.91 ± 0.02, and EGFR-Mutant had a performance of precision 0.76 ± 0.05, recall 0.71 ± 0.05, F1-score 0.68 ± 0.04. SHapley Additive exPlanations (SHAP) analysis identified tobacco use, enhancement pattern, and gray-level-zone entropy as key predictors. Decision curve analysis confirmed clinical utility, supporting its role as a non-invasive tool for EGFR-screening. Full article

Prostate cancer (PCa) diagnosis has historically relied on the prostate-specific antigen (PSA) testing. Although the screening significantly reduces mortality rates, PSA has low specificity with risks of overdiagnosis and overtreatment. These limitations highlight the need for a more accurate diagnostic approach. Emerging technologies, such as artificial intelligence (AI), novel biomarkers, and advanced imaging techniques, offer promising avenues to enhance the accuracy and efficiency of PCa diagnosis and risk stratification. This narrative review comprehensively analyzed the current literature, focusing on new tools aiding PCa diagnosis (AI-driven image interpretation, radiomics, genomic classifiers, biomarkers, and multimodal data integration) with consideration for technical, regulatory, and ethical challenges related to clinical implementation of AI-based technologies. A literature search was performed using the PubMed and MEDLINE databases to identify relevant peer-reviewed articles published in English using the search terms “prostate cancer,” “artificial intelligence,” “machine learning,” “deep learning,” “MRI,” “histopathology,” and “diagnosis.” Articles were selected based on their relevance to AI-assisted diagnostic tools, clinical utility, and performance metrics. In addition, a separate section was developed initially to contextualize the limitations of current PSA-based screening approaches. The reviewed studies showed that AI had significant utility in prostate mpMRI interpretation (lesion detection; Gleason grading) with high accuracy and high reproducibility. For the pathologist, AI-driven algorithms improve the diagnostic accuracy of digital slide evaluation for histologic diagnosis of prostate cancer and automated Gleason score grading. Genomic tools such as the Oncotype DX test, combined with AI, could also allow for tailored and individualized risk prediction. Overall, multimodal models integrating clinical, imaging, and molecular data often outperform traditional PSA-based strategies and reduce unnecessary biopsies. Transition from PSA-centered toward AI-driven, biomarker-supported, and image-enhanced diagnosis marks a critical evolution in PCa diagnosis. Full article

Introduction: Recurrence after pelvic exenteration remains a significant concern in patients with locally advanced rectal cancer (LARC). Therefore, there is a need for improved non-invasive predictive tools to aid in patient selection. Radiomics, which extracts quantitative imaging features, may help identify patients at greater risk of recurrence. This study aimed to develop and validate a radiomics-based nomogram using pre-treatment MRI to predict postoperative recurrence risk in LARC. Methods: The largest multicenter retrospective radiomics analysis of 191 patients with pathologically confirmed LARC treated at fourteen centres (2016–2018) was performed. All patients received neoadjuvant chemoradiotherapy followed by curative-intent exenterative surgery. Manual tumour segmentation was performed on pre-treatment T2-weighted MRI. Feature selection employed LASSO regression with 5-fold cross-validation across 1000 bootstrap samples. The most frequently selected features were used to construct a logistic regression model via stepwise backward selection. Model performance was assessed using ROC analysis, calibration plots, decision curve analysis, and internal validation with 1000 bootstraps. A nomogram was generated to enable individualized recurrence risk estimation. Results: Postoperative recurrence occurred in 51% (n = 98) of cases. Five radiomic features reflecting tumour heterogeneity, morphology, and texture were included in the final model. In multivariable analysis, all selected features were significantly associated with recurrence, with odds ratios ranging from 0.63 to 1.64. The model achieved an optimism-adjusted AUC of 0.70, indicating fair discrimination. Calibration plots showed good agreement between predicted and observed recurrence probabilities. Decision curve analysis confirmed clinical utility across relevant thresholds. A clinically interpretable nomogram was developed based on the final model. Conclusions: A radiomics-based model using preoperative MRI can predict recurrence in LARC. The derived nomogram provides a practical tool for preoperative risk assessment. Prospective validation is necessary. Full article

Background: Radiomics offers quantitative, high-dimensional data from conventional imaging and holds promise for improving diagnosis and treatment of pituitary adenomas (PAs). This systematic review aimed to synthesize current clinical applications of radiomics in PAs, focusing on diagnostic, predictive, and prognostic modeling. Methods: This review followed the PRISMA 2020 guidelines. A systematic search was performed in PubMed, Scopus, and Web of Science on 10 January 2024, and updated on 5 March 2024, using predefined keywords and MeSH terms. Studies were included if they evaluated radiomics-based models using MRI for diagnosis, classification, consistency, invasiveness, treatment response, or recurrence in human PA populations. Data extraction included study design, sample size, MRI sequences, feature types, machine learning algorithms, and model performance metrics. Study quality was assessed via the Newcastle-Ottawa Scale. Descriptive statistics summarized study characteristics; no meta-analysis was performed due to heterogeneity. Results: Out of 341 identified articles, 49 studies met inclusion criteria, encompassing a total of more than 9350 patients. The majority were retrospective (43 studies, 88%). MRI sequences used included T2-weighted imaging (35 studies, 71%), contrast-enhanced T1WI (34 studies, 69%), and T1WI (21 studies, 43%). PyRadiomics was the most common feature extraction tool (20 studies, 41%). Machine learning was employed in 43 studies (88%), predominantly support vector machines (16 studies, 33%), random forests (9 studies, 18%), and logistic regression (9 studies, 18%). Deep learning methods were applied in 17 studies (35%). Regarding diagnostic performance, 22 studies (45%) reported an (AUC) ≥0.85 in test datasets. External validation was performed in only 6 studies (12%). Radiomics applications included histological subtype prediction (14 studies, 29%), surgical outcome prediction (13 studies, 27%), invasiveness assessment (7 studies, 15%), tumor consistency evaluation (8 studies, 16%), and response to medical or radiotherapy treatments (3 studies, 6%). One study (2%) addressed automated segmentation and volumetry. Conclusions: Radiomics enables high-performance, noninvasive prediction of PA subtypes, consistency, invasiveness, treatment response, and recurrence, with 22 studies (45%) reporting AUC ≥0.85. Despite promising results, clinical translation remains limited by methodological heterogeneity, low external validation (6 studies, 12%), and lack of standardization. Full article

Background: Hepato-pancreato-biliary (HPB) surgery involves operations that depend heavily on precise imaging, careful planning, and intraoperative decision-making. The rapid emergence of artificial intelligence (AI) and digital tools has assisted in these domains. Methods: We performed a PRISMA-guided systematic review (searches through June 2025) of AI/digital technologies applied to HPB surgical care, including novel models such as machine learning, deep learning, radiomics, augmented/mixed reality, and computer vision. Our focus was for eligible studies to address imaging interpretation, preoperative planning, intraoperative guidance, or outcome prediction. Results: In total, 38 studies met inclusion criteria. Imaging models constructed with AI showed high diagnostic performance for lesion detection and classification (commonly AUC ~0.80–0.98). Moreover, risk models using machine learning frequently exceeded traditional scores for predicting postoperative complications (e.g., pancreatic fistula). AI-assisted three-dimensional visual reconstructions enhanced anatomical understanding for preoperative planning, while augmented and mixed-reality systems enabled real-time intraoperative navigation in pilot series. Computer-vision systems recognized critical intraoperative landmarks (e.g., critical view of safety) and detected hazards such as bleeding in near real time. Most of the studies included were retrospective, single-center, or feasibility designs, with limited external validation. Conclusions: The usage of AI and digital tools show promising results across the HPB pathway—from preoperative diagnostics to intraoperative safety and guidance. The evidence to date supports technical feasibility and suggests clinical benefit, but routine adoption and further conclusions should await prospective, multicenter validation and consistent reporting. With continued refinement, multidisciplinary collaboration, appropriate cost effectiveness, and attention to ethics and implementation, these technologies could improve the precision, safety, and outcomes of HPB surgery. Full article

Background: Glioblastoma (GBM) is a highly aggressive and heterogeneous primary malignancy of the central nervous system, with a median overall survival (OS) of approximately 15 months. Achieving accurate and generalizable OS prediction across multi-center settings is essential for clinical application. Methods: We propose a Personalized Habitat-aware Survival Prediction Network (PHSP-Net) that integrates multiparametric MRI with an adaptive habitat partitioning strategy. The network combines deep convolutional feature extraction and interpretable visualization modules to perform patient-specific subregional segmentation and survival prediction. A total of 1084 patients with histologically confirmed WHO grade IV GBM from four centers (UPENN-GBM, UCSF-PDGM, LUMIERE and TCGA-GBM) were included. PHSP-Net was compared with conventional radiomics, habitat imaging models and ResNet10, with independent validation on two external cohorts. Results: PHSP-Net achieved an AUROC of 0.795 (95% CI: 0.731–0.852) in the internal validation set, and 0.707 and 0.726 in the LUMIERE and TCGA-GBM external test sets, respectively—outperforming both comparison models. Kaplan–Meier analysis revealed significant OS differences between predicted high- and low-risk groups (log-rank p < 0.05). Visualization analysis indicated that necrotic-region habitats were key prognostic indicators. Conclusions: PHSP-Net demonstrates high predictive accuracy, robust cross-center generalization and improved interpretability in multi-center GBM cohorts. By enabling personalized habitat visualization, it offers a promising non-invasive tool for prognostic assessment and individualized clinical decision making in GBM. Full article

Background/Objectives: Accurate classification of brain tumors and reliable prediction of patient survival are essential in neuro-oncology, guiding clinical decisions and enabling precision treatment planning. However, conventional machine learning and deep learning methods often struggle with challenges such as data scarcity, class imbalance, limited model interpretability, and poor generalization across diverse clinical settings. This study presents GlioSurvQNet, a novel reinforcement learning-based framework designed to address these limitations for both glioma grading and survival prediction. Methods: GlioSurvQNet is built upon a DuelContextAttn Deep Q-Network (DQN) architecture, tailored for binary classification of low-grade vs. high-grade gliomas and multi-class survival prediction (short-, medium-, and long-term categories). Radiomics features were extracted from multimodal MRI scans, including FLAIR, T1CE, and T2 sequences. Feature optimization was performed using a hybrid ensemble of metaheuristic algorithms, including Harris Hawks Optimization (HHO), Modified Gorilla Troops Optimization (mGTO), and Zebra Optimization Algorithm (ZOA). Subsequently, SHAP-based feature selection was applied to enhance model interpretability and robustness. Results: The classification module achieved the highest accuracy of 99.27% using the FLAIR + T1CE modality pair, while the survival prediction model attained an accuracy of 93.82% with the FLAIR + T2 + T1CE fusion. Comparative evaluations against established machine learning and deep learning models demonstrated that GlioSurvQNet consistently outperformed existing approaches in both tasks. Conclusions: GlioSurvQNet offers a powerful and interpretable AI-driven solution for brain tumor analysis. Its high accuracy and robustness make it a promising tool for clinical decision support in glioma diagnosis and prognosis. Full article

Joint degeneration is a major global health issue requiring improved diagnostic and prognostic tools. This review examines whether integrating Bayesian graphical models with multiscale medical imaging can enhance detection, analysis, and prediction of joint degeneration compared to traditional single-scale methods. Recent advances in quantitative MRI, such as T2 mapping, enable early detection of subtle cartilage changes, supporting earlier intervention. Bayesian graphical models provide a flexible framework for representing complex relationships and updating predictions as new evidence emerges. Unlike prior reviews that address Bayesian methods or musculoskeletal imaging separately, this work synthesizes these domains into a unified framework that spans molecular, cellular, tissue, and organ-level analyses, providing methodological guidance and clinical translation pathways. Key topics within Bayesian inference include multiscale analysis, probabilistic graphical models, spatial-temporal modeling, network connectivity analysis, advanced imaging biomarkers, quantitative analysis, quantitative MRI techniques, radiomics and texture analysis, multimodal integration strategies, uncertainty quantification, variational inference approaches, Monte Carlo methods, and model selection and validation, as well as diffusion models for medical imaging and Bayesian joint diffusion models. Additional attention is given to diffusion models for advanced medical image generation, addressing challenges such as limited datasets and patient privacy. Clinical translation and validation requirements are emphasized, highlighting the need for rigorous evaluation to ensure that synthesized or processed images maintain diagnostic accuracy. Finally, this review discusses implementation challenges and outlines future research directions, emphasizing the potential for earlier diagnosis, improved risk assessment, and personalized treatment strategies to reduce the growing global burden of musculoskeletal disorders. Full article